Stability of Oral Oxytocics in Tropical Climates - Results of Simulation Studies on Oral Ergometrine, Oral Methylergometrine, Buccal Oxytocin and Buccal Desamino-Oxytocin - EDM Research Series No. 012
(1994; 52 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Afficher le documentSummary
Ouvrir ce répertoire et afficher son contenuIntroduction
Ouvrir ce répertoire et afficher son contenuMaterials and methods
Ouvrir ce répertoire et afficher son contenuResults
Ouvrir ce répertoire et afficher son contenuDiscussion
Afficher le documentConclusions and recommendations
Afficher le documentReferences
Fermer ce répertoireAnnexes
Afficher le documentAnnex 1: Ergometrine 0.2 mg tablets
Afficher le documentAnnex 2: Methylergometrine 0.125 mg tablets
Afficher le documentAnnex 3: Buccal oxytocin 200 IU
Afficher le documentAnnex 4: Buccal desamino-oxytocin, 50 IU
Afficher le documentAnnex 5: Summary of results
Afficher le documentAnnex 6: Figures 1 to 7
 

Annex 1: Ergometrine 0.2 mg tablets

Stated amount: 147µg free base ergometrine (=100%) test I: D6/83

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.148

100.7

0.014

9.5

4

7

0.125

85.1

0.005

4.0

4

14

0.130

88.4

0.005

3.8

4

21

0.096

65.3

0.002

2.1

4

30

0.096

65.3

0.003

3.1

4

40

0.085

57.8

0.002

2.4

4

52

0.079

53.7

0.004

5.1

16

test II: D20/75

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.104

70.7

0.022

21.1

4

7

0.108

73.5

0.002

1.9

4

14

0.095

64.6

0.008

8.4

4

21

0.049

33.3

0.003

6.1

4

30

0.045

30.6

0.002

4.4

4

40

0.032

15.3

0.001

3.1

4

52

0.023

15.6

0.002

8.7

20

test III: D30/45

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.093

63.3

0.014

15.1

4

7

0.120

81.6

0.008

6.7

4

14

0.099

67.3

0.001

1.0

4

21

0.074

50.3

0.003

4.1

4

30

0.067

45.6

0.003

4.5

4

40

0.059

40.1

0.000

0

2

52

0.054

36.7

0.003

5.6

20

Ergometrine 0.2 mg tablets test IV: D30/75

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.124

84.4

0.013

10.5

4

7

0.084

57.1

0.005

8.5

4

14

0.058

39.5

0.004

6.9

4

21

0.034

23.1

0.002

5.9

4

30

0.031

21.1

0.002

6.5

4

40

0.019

12.9

0.001

5.3

3

52

0.013

8.8

0.002

15.4

20

test V: D40/25

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.095

64.4

0.012

12.6

4

7

0.113

76.9

0.010

8.8

4

14

0.102

69.4

0.003

2.9

4

21

0.078

53.1

0.005

6.4

4

30

0.077

52.4

0.005

6.5

4

40

0.074

50.3

0.001

1.4

4

52

0.066

44.9

0.010

15.0

20

test VI: D40/75

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.039

26.5

0.008

20.5

4

7

0.018

12.2

0.006

33.3

4

14

0.005

3.4

0.001

20

4

21

0.002

1.4

0.000

0

4

30

0.001

0.7

0.000

0

4

40

0.002

1.4

0.000

0

4

52

0.001

0.7

0.001

100

8

Ergometrine 0.2 mg tablets

test VII: L 20/30

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

0.008

5.6

20

3

0.090

61.2

0.010

11.1

4

7

0.095

64.6

0.008

8.4

4

14

0.077

52.4

0.009

11.7

4

21

0.073

49.7

0.006

8.2

4

30

0.073

49.7

0.003

4.1

4

40

0.068

46.3

0.002

2.9

4

52

0.065

44.2

0.003

4.6

18

Ergometrine 0.2 mg tablets

test VII: L 20/30; packed in aluminium foil

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

0

0.142

96.6

   

20

12

0.095

64.6

   

4

20

0.087

59.2

   

2

41

0.087

59.2

   

4

test VII: L20/30; packed in sealed poly ethylene

time (weeks)

mean conc/tablet (HPLC)

% HPLC

SD

SD/mean x100% CV%

n

41

0.079

54.4

   

11

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019